AbbVie Inc. (ABBV)
BMV
Closed
Aug 21, 2026
Day's Range
4,495.0052 wk Range
3,420.00Overview - ABBV - AbbVie Inc.
Key Statistics
Valuation
Enterprise Value
135.29T
P/E (Trailing)
‪75.19‬
PEG Ratio
‪0.26‬
Price / Sales (TTM)
‪123.36‬
Price / Book
‪-1,350.48‬
EV / EBITDA
‪260.29‬
Profitability
Gross Margin
‪74.74%‬
Profit Margin
‪9.80%‬
Operating Margin
‪40.03%‬
Return on Assets
‪10.51%‬
Return on Equity
‪-129.67%‬
Ownership
Shares Outstanding
1.76B
Float
1.76B
Held by Insiders
‪0.11%‬
Held by Institutions
‪77.43%‬
Price stats
Beta
‪0.28‬
50-Day Avg
‪4,304.36‬
200-Day Avg
‪3,988.14‬
Dividends
Payout Ratio
‪190.39%‬
Frequency
Quarterly
Shariah Compliance
Report Date: Feb 18, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ABBV - AbbVie Inc.
Peers - ABBV - AbbVie Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on BMV.
Profile Summary - ABBV - AbbVie Inc.
About
AbbVie Inc. is a research-based biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative medicines and therapies worldwide. The company maintains a strong focus on immunology, offering treatments like Humira, Skyrizi, and Rinvoq for autoimmune and inflammatory conditions in…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
